Skip to main content
Top
Published in: Rheumatology International 8/2013

01-08-2013 | Original Article

Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients

Authors: Hadi Poormoghim, Alireza Salek Moghadam, Maziar Moradi-Lakeh, Mehrzad Jafarzadeh, Behnam Asadifar, Mohsen Ghelman, Elham Andalib

Published in: Rheumatology International | Issue 8/2013

Login to get access

Abstract

To evaluate demographic, clinical and laboratory features associated with scleroderma-specific auto-antibodies. Sera of 100 patients with systemic sclerosis (SSc) were analyzed by an indirect immunofluorescence technique with HEp-2 cells as a substrate. Specific ANA such as anti-centromere antibodies (ACA), anti-topoisomerase (TOPO), anti-RNA polymerase III (Pol 3), anti-U3-RNP (U3-RNP), anti-Th/To (Th/To) and anti-PM/Scl (PM/Scl) were detected by line immunoassay and anti-U1-RNP (U1-RNP) by ELISA. Frequency of clinical features associated with a specific antibody group was reported cumulatively over the follow-up period. Frequency of specific clinical features was compared across the two disease subtype including limited cutaneous (lcSSc) or diffuse cutaneous (dcSSc) as well as the auto-antibody groups. Ninety-four percent of patients were ANA positive with significant higher skin score, Raynauds and digital ulcer/gangrene. Anti-TOPO was detected in 71 % of all patients, in 90.5 % of dcSSC and in 65.8 % of lcSSc. Anti-TOPO was significantly associated with dcSSc, higher skin score, digital ulcer/gangrene, pulmonary fibrosis, DLCO <70 %. U1-RNP antibody was associated with lower fibrosis in lung. ACA was positive in 7 % of patients and exclusively in those with lcSSc. We did not find association between gender and presence of auto-antibodies. Anti-TOPO antibody had a high prevalence in contrast to low prevalence of ACA antibody. There were no differences in clinical subtypes of the disease in patients with positive anti-TOPO and positive ACA. Differences in prevalence of auto-antibodies are suggestive of further genetic study.
Literature
1.
go back to reference Koenig M, Dieude M, Senecal JL (2008) Predictive value of antinuclear antibodies: the lessons of systemic sclerosis autoantibodies. Autoimmun Rev 7:588–593PubMedCrossRef Koenig M, Dieude M, Senecal JL (2008) Predictive value of antinuclear antibodies: the lessons of systemic sclerosis autoantibodies. Autoimmun Rev 7:588–593PubMedCrossRef
3.
go back to reference Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestation in systemic sclerosis: a report from the EULAR Scleroderma Trial and Research group database. Ann Rheum Dis 66:754–763PubMedCrossRef Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestation in systemic sclerosis: a report from the EULAR Scleroderma Trial and Research group database. Ann Rheum Dis 66:754–763PubMedCrossRef
5.
go back to reference Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9:R78. doi:10.1186/ar2276 PubMedCrossRef Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9:R78. doi:10.​1186/​ar2276 PubMedCrossRef
6.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and patogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and patogenesis. J Rheumatol 15:202–205PubMed
7.
go back to reference Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Du Bountin LTH et al (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interestial lung disease. Arthritis Rheum 54:181–191CrossRef Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Du Bountin LTH et al (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interestial lung disease. Arthritis Rheum 54:181–191CrossRef
8.
go back to reference Medsger TA Jr, Steen VD (1996) Classification, prognosis. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams & Wilkins, Baltimore, MD, pp 51–64 Medsger TA Jr, Steen VD (1996) Classification, prognosis. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams & Wilkins, Baltimore, MD, pp 51–64
9.
go back to reference Sack U, Conrad K, Csernok E, Frank I, Hiepe F, Krieger T et al (2009) Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann N Y Acad Sci 1173:166–173PubMedCrossRef Sack U, Conrad K, Csernok E, Frank I, Hiepe F, Krieger T et al (2009) Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann N Y Acad Sci 1173:166–173PubMedCrossRef
10.
go back to reference Hanke K, Dahnrich C, Bruckner C, Huscher D, Becker M, Janssen A et al (2009) Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 11:R28PubMedCrossRef Hanke K, Dahnrich C, Bruckner C, Huscher D, Becker M, Janssen A et al (2009) Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 11:R28PubMedCrossRef
11.
go back to reference Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelstssi C, La Montagna G et al (2002) Systemic sclerosis, demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 81:139–159PubMedCrossRef Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelstssi C, La Montagna G et al (2002) Systemic sclerosis, demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 81:139–159PubMedCrossRef
13.
go back to reference Jacobsen S, Halberg P, Ullman S (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37:750–755PubMedCrossRef Jacobsen S, Halberg P, Ullman S (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37:750–755PubMedCrossRef
14.
go back to reference Solomon DH, Kavanaugh AJ, Schur PH (2002) The American College of Rheumatology Ad Hoc Committee on immunologic testing guidelines evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47:434–444PubMedCrossRef Solomon DH, Kavanaugh AJ, Schur PH (2002) The American College of Rheumatology Ad Hoc Committee on immunologic testing guidelines evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 47:434–444PubMedCrossRef
15.
go back to reference Hesselstrand R, Scheja A, Shen GO, Wiik A, Akesson AT (2003) The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 42:534–540PubMedCrossRef Hesselstrand R, Scheja A, Shen GO, Wiik A, Akesson AT (2003) The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 42:534–540PubMedCrossRef
16.
go back to reference Vazquez-Abad D, Wallace S, Senecal JL, Joyal F, Roussin A, Earnshaw WC, Rothfield N (1994) Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. Arthritis Rheum 37:248–252PubMedCrossRef Vazquez-Abad D, Wallace S, Senecal JL, Joyal F, Roussin A, Earnshaw WC, Rothfield N (1994) Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. Arthritis Rheum 37:248–252PubMedCrossRef
17.
go back to reference McNeilage LJ, Youngchaiyud U, Whittingham S (1989) Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 32(1):54–60PubMedCrossRef McNeilage LJ, Youngchaiyud U, Whittingham S (1989) Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 32(1):54–60PubMedCrossRef
18.
go back to reference Steen DV, Powell LD, Medsger AT (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196–203PubMedCrossRef Steen DV, Powell LD, Medsger AT (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196–203PubMedCrossRef
19.
go back to reference Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA (1998) African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 114:801–807PubMedCrossRef Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA (1998) African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 114:801–807PubMedCrossRef
20.
go back to reference Bernstein RM, Steigerwald JC, Tan EM (1982) Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 48:43–51PubMed Bernstein RM, Steigerwald JC, Tan EM (1982) Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol 48:43–51PubMed
21.
go back to reference Stupi AM, Steen VD, Owen GR, Barnes EL, Rodnan GP, Medsger TA Jr (1986) Pulmonary hypertension (PTH) in the CREST syndrome variant of progressive sclerosis (PSS). Arthritis Rheum 29:515–524PubMedCrossRef Stupi AM, Steen VD, Owen GR, Barnes EL, Rodnan GP, Medsger TA Jr (1986) Pulmonary hypertension (PTH) in the CREST syndrome variant of progressive sclerosis (PSS). Arthritis Rheum 29:515–524PubMedCrossRef
22.
go back to reference Tormey VJ, Bunn CC, Denton CP, Black CM (2001) Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 40:1157–1162PubMedCrossRef Tormey VJ, Bunn CC, Denton CP, Black CM (2001) Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 40:1157–1162PubMedCrossRef
23.
go back to reference Okano Y, Steen VD, Medsger ATA Jr (1992) Autoantibody to U3 nucleolar ribonucleoprotein (fibrilliarin) in patients with systemic sclerosis. Arthritis Rheum 35:95–100PubMedCrossRef Okano Y, Steen VD, Medsger ATA Jr (1992) Autoantibody to U3 nucleolar ribonucleoprotein (fibrilliarin) in patients with systemic sclerosis. Arthritis Rheum 35:95–100PubMedCrossRef
24.
go back to reference Primer G, Steen VD, Penning CA, Medsger T, Tan EM (1988) Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis. Arthritis Rheum 31:525CrossRef Primer G, Steen VD, Penning CA, Medsger T, Tan EM (1988) Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis. Arthritis Rheum 31:525CrossRef
25.
go back to reference Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75–83PubMedCrossRef Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37:75–83PubMedCrossRef
26.
go back to reference Harvey G, Black C, Maddison P, McHugh N (1997) Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 24:477–484PubMed Harvey G, Black C, Maddison P, McHugh N (1997) Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 24:477–484PubMed
27.
go back to reference Chang M, Wang R, Yangco D, Sharp G, Komatireddy G, Hoffman R (1998) Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopath 89:71–78CrossRef Chang M, Wang R, Yangco D, Sharp G, Komatireddy G, Hoffman R (1998) Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopath 89:71–78CrossRef
28.
go back to reference Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T et al (2009) Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunoassay. Rheumatology 48:1570–1574PubMedCrossRef Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T et al (2009) Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunoassay. Rheumatology 48:1570–1574PubMedCrossRef
29.
go back to reference Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM (1998) Anti-RNA polymerase and other autoantibody specification in systemic sclerosis. Br J Rheumatol 37:15–20PubMedCrossRef Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM (1998) Anti-RNA polymerase and other autoantibody specification in systemic sclerosis. Br J Rheumatol 37:15–20PubMedCrossRef
30.
go back to reference Okano Y, Steen VD, Medsger TA Jr (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005–1013PubMedCrossRef Okano Y, Steen VD, Medsger TA Jr (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005–1013PubMedCrossRef
31.
go back to reference Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP (2009) A longitudinal study of anti-RNA polymerase III antibody level in systemic sclerosis. Rheumatology 48:1218–1221PubMedCrossRef Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP (2009) A longitudinal study of anti-RNA polymerase III antibody level in systemic sclerosis. Rheumatology 48:1218–1221PubMedCrossRef
32.
go back to reference Altman RD, Medsger TA Jr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413PubMedCrossRef Altman RD, Medsger TA Jr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413PubMedCrossRef
33.
go back to reference Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 14(1):111–124PubMedCrossRef Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 14(1):111–124PubMedCrossRef
34.
go back to reference Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Sato S et al (1999) Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol 117:383–387PubMedCrossRef Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Sato S et al (1999) Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol 117:383–387PubMedCrossRef
35.
go back to reference Reveille JD, Solomon DH (2003) American College of Rheumatology, Ad Hoc Committee on immunological testing guidelines evidence-based guidelines for the use of immunologic laboratory tests: anti-centromere, Scl-70 and nucleolar antibodies. Arthritis Rheum 15(49):399–412CrossRef Reveille JD, Solomon DH (2003) American College of Rheumatology, Ad Hoc Committee on immunological testing guidelines evidence-based guidelines for the use of immunologic laboratory tests: anti-centromere, Scl-70 and nucleolar antibodies. Arthritis Rheum 15(49):399–412CrossRef
36.
go back to reference Dick T, Mierau R, Bartz-Bazzanaella P (2002) Coexistence of antitopoisomeras and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 61:121–127PubMedCrossRef Dick T, Mierau R, Bartz-Bazzanaella P (2002) Coexistence of antitopoisomeras and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 61:121–127PubMedCrossRef
37.
go back to reference Kuwana M, Kimura K, Hirakata M (2002) Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 61:842–846PubMedCrossRef Kuwana M, Kimura K, Hirakata M (2002) Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 61:842–846PubMedCrossRef
Metadata
Title
Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients
Authors
Hadi Poormoghim
Alireza Salek Moghadam
Maziar Moradi-Lakeh
Mehrzad Jafarzadeh
Behnam Asadifar
Mohsen Ghelman
Elham Andalib
Publication date
01-08-2013
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 8/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2668-5

Other articles of this Issue 8/2013

Rheumatology International 8/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.